Scott Chappel, Ph.D.
Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held several senior leadership roles in companies developing novel therapies in oncology and other areas. Scott also serves as a Scientific Advisor to MPM portfolio company iTeos Therapeutics (NASDAQ: ITOS).
Prior to joining MPM, Scott was a founder and Chief Technology Officer at Surface Oncology, where he oversaw all antibody generation, engineering, production, characterization and manufacturing as well as all preclinical IND-enabling studies. He was also a founder and CSO at Arteaus Therapeutics which developed an antibody for the prevention of migraine headaches (acquired by Eli Lilly) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer. Prior to Tokai, he held roles as a Senior Vice President of Research at Dyax and as a Chief Scientist at Serono.
Scott has authored or co-authored more than 65 peer-reviewed scientific publications and been named inventor on 24 issued U.S. patents. He received his Ph.D. in Neuroscience from the University of Maryland School of Medicine.